The role of melatonin in the onset and progression of type 3 diabetes

Juhyun Song¹, Daniel J. Whitcomb² and Byeong C. Kim³*

Abstract

Alzheimer’s disease (AD) is defined by the excessive accumulation of toxic peptides, such as beta amyloid (Aβ) plaques and intracellular neurofibrillary tangles (NFT). The risk factors associated with AD include genetic mutations, aging, insulin resistance, and oxidative stress. To date, several studies that have demonstrated an association between AD and diabetes have revealed that the common risk factors include insulin resistance, sleep disturbances, blood brain barrier (BBB) disruption, and altered glucose homeostasis. Many researchers have discovered that there are mechanisms common to both diabetes and AD. AD that results from insulin resistance in the brain is termed “type 3 diabetes”. Melatonin synthesized by the pineal gland is known to contribute to circadian rhythms, insulin resistance, protection of the BBB, and cell survival mechanisms. Here, we review the relationship between melatonin and type 3 diabetes, and suggest that melatonin might regulate the risk factors for type 3 diabetes. We suggest that melatonin is crucial for attenuating the onset of type 3 diabetes by intervening in Aβ accumulation, insulin resistance, glucose metabolism, and BBB permeability.

Keywords: Melatonin, Type 3 diabetes, Alzheimer’s disease (AD), Insulin resistance, Hyperglycemia, Blood brain barrier (BBB), Beta amyloid (Aβ)

Introduction

Alzheimer’s disease (AD) is an age-related neurodegenerative disorder that is characterized by the abnormal aggregation and accumulation of toxic peptides resulting in beta amyloid (Aβ) plaques and intracellular neurofibrillary tangles (NFT) [1]. According to recent reports, the number of patients with AD will be over 13.8 million by 2050, which will place a tremendous burden on society globally [2–4]. The onset of AD is linked to various causes, such as genetic mutations [5, 6], sex [7], lipid metabolism [8–11], aging [12–14], and diet [9, 15]. AD pathology results from excessive oxidative stress, synaptic loss, neuronal cell death, impaired insulin signaling, and abnormal glucose metabolism [16–18]. Cohort studies have demonstrated that type 2 diabetes (T2DM) increases the risk of dementia and results from common risk factors associated with dementia, including insulin resistance and hyperglycemia [19]. Many patients with metabolic diseases, such as cardiovascular disease, diabetes, and obesity, are reported to have a progressive decline in cognitive function, leading to the development of AD [20, 21]. One meta-analysis showed that diabetes significantly increases the risk for AD in elderly people [22]. Owing to the common risk factors between diabetes and AD, recent studies have proposed that AD is a brain-specific type of diabetes, which they termed “type 3 diabetes” [17, 23–25].

Melatonin (N-acetyl-5-methoxytryptamine) is mainly secreted as a neurohormone by the pineal gland [26]. It plays a role in various physiological functions, including circadian rhythm regulation, antioxidant activities, and the regulation of mitochondrial function [27–30]. Given that sleep disorders frequently occur in up to 45% of patients with AD [31–33], melatonin is an important hormone for the treatment of AD since it corrects abnormal sleep patterns [34, 35]. In AD, melatonin levels are decreased in the cerebrospinal fluid (CSF) compared to those in the normal population [36, 37]. Several studies have demonstrated that melatonin reduces Aβ accumulation [38], tau hyperphosphorylation [39], synaptic dysfunction [40], and blood brain barrier (BBB) permeability [41]. Moreover, melatonin attenuates insulin resistance [42], and regulates glucose homeostasis [43, 44]. In this review,
we summarize the therapeutic functions of melatonin in type 3 diabetes from various perspectives.

The risk factors for diabetes contribute to the onset and progression of Alzheimer’s disease

Insulin resistance leads to cognitive decline

Diabetes is characterized by insulin resistance, diminished pancreatic beta-cell function, and abnormally high glucose levels [45]. Diabetes is commonly classified into two types, namely, type 1 (T1DM) and T2DM [45]. T2DM occurs more frequently in the global population than T1DM and is accompanied by insulin resistance, hyperglycemia, cognitive decline, and impaired circadian rhythms [46, 47]. T2DM is known to be associated with cognitive impairments [48], and is commonly used as an index for the development of vascular dementia [49], and AD [50, 51]. The high prevalence of central nervous system (CNS) diseases in patients with diabetes has already been revealed by global reports [52–55]. The onset and progression of AD is associated with the capacity of the brain to utilize glucose for energy production [56, 57]. In the CNS, insulin signaling plays central roles in the cognitive dysfunction found in AD [58]. Insulin is known to be neuroprotective and has powerful effects on memory [59]. Previous studies have shown that deficiencies in insulin receptors (IRs) in the brain, a factor implicated in insulin resistance, leads to memory dysfunction [18, 60]. IRs are localized in cerebral regions, such as the hippocampus, amygdala, and septum [61, 62]. AD patients show an 80% reduction in IRs in their brains compared to normal subjects [17]. Consequently, insulin signaling is abnormal [63]. Some studies have demonstrated that the hippocampus regulates the consolidation of memory via insulin signaling [64, 65]. Based on this evidence, decreased insulin levels were subsequently found in the CSF of patients with AD and mild cognitive impairment (MCI) [60, 66, 67]. Aβ accumulation, abnormalities in the cholinergic system, tau hyperphosphorylation, and damage to neuronal cells contribute to impaired insulin signaling [68, 69]. Insulin receptors deficiency in the AD brain results in insulin resistance in AD neuropathology [18, 70]. For these reasons, reduced levels of insulin receptor genes may contribute to the progression of AD [23, 71]. Moreover, tau pathology in AD is mediated by impaired tau gene expression owing to the attenuation in insulin signaling [72, 73]. Insulin resistance in the AD brain reduces the phosphorylation of phosphoinositol-3-kinase (PI3K), and Akt [72, 73], which ordinarily function to promote neuronal growth and survival, and promotes GABAergic transmission involved in learning and memory [74], and blocks the accumulation of Aβ [75]. Additionally, insulin resistance increases the activation of glycogen synthase kinase (GSK-3) [76, 77], which is related to the hyperphosphorylation of tau and the acceleration of tau misfolding [78]. Indeed, owing to deficiencies in insulin, the change of GSK-3 activity leads to the hyperphosphorylation of tau [79], perhaps unsurprising given what we know about the aberrant activation of GSK-3β and the resultant Aβ accumulation and tau protein phosphorylation [80, 81]. Moreover, several clinical studies have demonstrated a positive correlation between diabetes and AD [57, 82], and suggested that the central reasons for this include aberrant insulin signaling and dementia [58, 83–85]. In vivo studies, an AD mouse model showed insulin resistance [24], reduced glucose metabolism, oxidative stress, and cognitive impairments [86] following injections of streptozotocin (STZ). In addition, insulin resistance leads to hippocampal neuronal loss owing to amyloid neurotoxicity [68], reduced glucose uptake by inhibiting the expression of glucose transporters in cell membrane [87], and accelerated amyloid aggregation during early AD [88]. Consequently, insulin resistance and impaired insulin signaling are significantly related to tau hyperphosphorylation and Aβ deposition in AD, and ultimately contribute to cognitive decline [69] (Fig. 1).

Hyperglycemia triggers BBB disruption leading to cognitive dysfunction

According to previous studies, hyperglycemia in T2DM leads to cognitive dysfunction [89–91]. An abnormal glycemic condition is one of the main causes of BBB breakdown in patients with diabetes [92, 93]. Several studies demonstrated that the loss of tight junction proteins which make up the BBB and the activation of matrix metalloproteinases (MMPs) was shown in hyperglycemia in vivo model [94] and in patients [95, 96]. The BBB is comprised of brain endothelial cells lining the cerebral microvessels with astrocytic end-feet processes. The BBB endothelium is characterized by specific transmembrane transport systems that control the trafficking of small molecules in and out of
the brain parenchyma [97]. Glucose, the primary energetic source in the brain, can cross the BBB through transporter proteins, such as facilitative sodium independent transporters (e.g., the glucose transporter [GLUT]) [98, 99]. One animal study has shown downregulation of BBB glucose transporters in hyperglycemic mice compared to wild-type mice [100]. In chronic hyperglycemia conditions, GLUT1 and GLUT3 expression was attenuated in diabetic animal brain and subsequently aberrant GLUT1's expression triggers neuronal cell damage [100]. In addition, many studies have reported that the BBB in the diabetic brain has increased permeability owing to the activation of hypoxia-inducible factor-1α (HIF-1α) and increased levels of vascular endothelial growth factor (VEGF) [101, 102]. Hyperglycemia promotes the production of reactive oxygen species (ROS) [103, 104] and downregulates glucose transporters in brain endothelial cells [105]. Moreover, hyperglycemia aggravates amyloid toxicity, independent of insulin resistance [106]. Numerous studies have demonstrated that diet-induced hyperglycemia triggers an increase in BBB permeability and BBB damage [107]. The expression of IgG as the marker of BBB permeability was increased and tight junction proteins were attenuated in a hyperglycemia model [107]. In AD, BBB disruption promotes tau hyperphosphorylation [108, 109]. BBB disruption decreases the expression of glucose transporters [110], promotes ROS production [111] and increases infiltration of inflammatory mediators [112]. Tau aggregation is associated with increase of inflammation [112] and reduction of glucose transporters [110]. In addition, BBB dysfunction in AD contributes to Aβ clearance, activates glial cells, and aggravates inflammation by recruiting leukocytes to the brain [113]. Given this evidence, hyperglycemia-induced BBB disruption might play an important role in the onset and progression of AD (Fig. 2).

Melatonin in AD

Melatonin has been shown to have neuroprotective effects in a mouse model of AD [114, 115], since it attenuates Aβ accumulation and synaptic dysfunction by stabilizing the mitochondria function and inhibiting DNA damage [38, 40]. Melatonin controls several molecular signaling pathways, such as PI3/Akt/GSK3β and hemoxygenase-1 [39, 116, 117], and free radical scavenging mechanisms [118, 119] in the AD brain. A recent study demonstrated that melatonin improves synapse dysfunction via the Notch1/Hes1 signaling pathway in the hippocampus [120]. Another study suggested that melatonin inhibits apoptotic mediators and promotes pro-survival signaling in a model of AD [121]. An animal study demonstrated that chronic melatonin treatment for 30 days improves memory impairments in the AD mouse model [117]. Moreover, in patients with AD, melatonin levels were significantly decreased in the serum and CSF, and levels of melatonin were considered as a candidate risk factor for diagnosis of AD [37, 122]. Clinically, melatonin and its agonist have been regarded as treatments for AD [123, 124]. As mentioned above, melatonin has the potential to attenuate AD pathology via numerous mechanisms including PI3K/Akt/GSK3β [37] and Notch1 signaling [120], and RAGE/NF-κB/JNK signaling pathway [117]. Future study of the specific mechanisms of melatonin in the CNS is necessary to identify potential therapeutic solutions for AD.

The relationship between melatonin and type 3 diabetes

**Melatonin protects cells against Aβ toxicity and inhibits tau hyperphosphorylation**

Aβ, the main component of amyloid plaques, is believed to cause memory dysfunction [125]. Melatonin improves soluble Aβ-induced memory dysfunction and synaptic dysfunction via the Musashi1/Notch1/Hes1 signaling pathway [120], suggesting that the modulation of Notch1 could restore neurogenesis and cognitive function in AD models [126]. According to the results of an in vivo study, melatonin administration inhibits the expression of amyloid precursor protein-cleaving secretases in the hippocampus [127]. In addition, melatonin attenuates the memory impairments induced by Aβ accumulation in a sporadic AD model [38, 128, 129]. Melatonin inhibits the transcription of β-secretases via the melatonin receptors in SH-SY5Y neuronal cells [130]. Melatonin attenuates Aβ-induced memory dysfunction and tau hyperphosphorylation via the PI3/Akt/GSK3β pathway in the mouse brain [39]. Melatonin suppresses the activity of GSK3β through activation of p-GSK3β (Ser9) in Aβ in vitro model [131]. Moreover, it improves Aβ-induced impairments in hippocampal long-term potentiation (LTP) in rats [132].
Melatonin inhibits superoxide anion production in microglia under conditions of Aβ toxicity [115]. In addition, it inhibits memory dysfunction and tau phosphorylation in rats [133]. Considering the effect of melatonin on Aβ toxicity and tau hyperphosphorylation in AD, melatonin may be a key to improving memory function by suppressing the cell damage induced by Aβ toxicity and tau hyperphosphorylation.

**Melatonin protects cells against insulin resistance and hyperglycemia**

Diabetes is accompanied by dysregulation of the circadian system [134]. This is interesting given that glucose metabolism is regulated by the circadian system [135, 136]. In animals and humans with diabetes, increased insulin levels and abnormal glucose metabolism triggers aberrant circadian rhythms [42, 137]. One study demonstrated that a reduction of melatonin levels in serum is linked with high insulin levels in T2DM rats [42]. Moreover, Sakotnik et al. suggested that polymorphisms in the melatonin receptor gene are related to fasting blood glucose levels and increases in the prevalence of T2DM [138]. Several genome wide studies have shown that specific single nucleotide polymorphisms of the melatonin receptor 2 (MTNR1B) locus are related to the high glucose levels found in T2DM [139–141]. Genome-wide studies have shown that allelic variations in the melatonin receptor 2 (MT2) contribute to the elevations in fasting glucose levels in plasma, insulin resistance, and ultimately the risk for type 2 diabetes [142, 143]. Type 3 diabetes is related to the prevalence of T2DM and results from insulin resistance and hyperglycemia [144–146]. Therefore, a method of reducing the cell damage induced by insulin resistance and hyperglycemia is crucial in both diabetes and AD. Melatonin activates the expression of the MT2 receptor, which can inhibit the secretion of insulin from pancreatic β-cells [147, 148]. Numerous studies have shown that melatonin contributes to glucose homeostasis and that low glucose levels are present in patients with T2DM [137, 149]. A recent study has shown that loss of the melatonin receptor contributes to the activation of pancreatic islet hormones, and hepatic glucose transporters (Glut1 and 2) [150]. Melatonin attenuates the glucose-mediated release of insulin from pancreatic cells [151]. The reduction in melatonin secretion induced by nocturnal light exposure is a crucial factor for T2DM development [136, 152, 153]. Furthermore, the melatonin receptor 1 (MT1) is involved in the regulation of glucose homeostasis and stimulates the secretion of insulin to induce glucose uptake [43]. In humans, melatonin administration attenuates glucose tolerance and insulin resistance [44]. Melatonin could suppress mitochondrial dysfunction against insulin resistance in Male Zucker diabetic fatty rats [154]. Furthermore, melatonin attenuates the secretion of pro inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor (TNF)-α, interferon (IFN)-γ under insulin resistance condition in high fat diet mouse [155]. Melatonin is associated with metabolic pathways involved with the insulin pathway [156–158]. The phosphorylation of IRS-1, leading to the activation of phosphoinositide 3-kinase (PI-3 K), and SHP-2 protein was increased by melatonin [159, 160]. In the AD brain, the disturbance of insulin signaling is linked to the senile plaques formation [80, 161]. An impaired insulin receptor signaling triggers the decrease of insulin-mediated activation of PI-3 K/Akt signaling, resulting in hyperactivity of GSK-3 that induces tau hyperphosphorylation and Aβ accumulation [162]. The administration of melatonin rescues insulin receptor mechanisms and increases the activity of PI-3 K/Akt signaling and less Aβ accumulation and less tau hyperphosphorylation [163] (Fig. 3). One study suggested that the lack of melatonin by pinealectomy reduced insulin sensitivity [164]. The reduction of insulin levels in T1DM are linked to high melatonin levels in plasma [165]. Taking these results together, melatonin appears to be involved in the genesis of diabetes [42].
accompanied by insulin resistance and high glucose, and may influence the cognitive dysfunction in diabetes-induced AD (Fig. 4). In this sense, melatonin may be a key molecule in the pathogenesis of Type 3 diabetes.

**Melatonin protects the BBB against hyperglycemia**
Several studies have shown that disruption of the BBB is strongly associated with cognitive dysfunction in AD [166, 167]. The BBB is a heterogeneous structure that consists of various cells important for transferring nutrients and oxygen into brain, and disruption of the BBB has been observed in patients with T2DM [168, 169]. Increases in glucose levels in the blood leads to impaired neurovascular coupling [170, 171], and increased vascular permeability [172]. Hyperglycemia-induced increases in BBB permeability lead to cognitive decline and the development of AD [101]. Hyperglycemia-induced ROS results in BBB disruption and triggers cognitive decline [101]. Dysfunction of metabolic pathways, owing to BBB disruption in diabetes, leads to cognitive deficits [173, 174]. In an in vivo study, STZ-induced diabetes results in increased BBB permeability [101]. Impaired BBB function in diabetes may be a strong risk factor for the development of AD [175, 176]. The excessive generation of ROS in T2DM has been shown to increase BBB permeability by changing tight junction protein expression [177, 178]. According to recent studies, melatonin protects BBB integrity in brain microvascular endothelial cells against inflammation [179], and protects against cerebral endothelial cell dysfunction via nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-2 [180]. Moreover, melatonin prevents the increase in BBB permeability by inhibiting matrix metalloproteinase-9 expression [41]. In addition, melatonin protects against the loss of tight junction proteins and BBB disruption by promoting anti-inflammatory and antioxidant mediators, and axonal regrowth [29]. Melatonin reduces the oxidative stress-induced generation of ROS in brain endothelial cells [181], and ameliorates BBB permeability and nitric oxide levels caused by oxidative stress [182, 183]. In addition, melatonin protects against the degradation of tight junction proteins, BBB disruption, serves as an anti-inflammatory and angiogenesis regulator, and promotes axonal regrowth under high glucose conditions [29, 184]. Based on previous reports, melatonin might alleviate BBB breakdown in diabetes-induced AD by inhibiting the loss of tight junction and the increase of BBB permeability (Fig. 5).

**Conclusions and prospects**
Diabetes-induced AD has been called “type 3 diabetes” owing to the common risk factors, which include insulin resistance and hyperglycemia. Here, we reviewed the effect of melatonin in type 3 diabetes from various angles. Melatonin influences type 3 diabetes by 1) suppressing Aβ toxicity and tau hyperphosphorylation, 2) controlling insulin resistance and hyperglycemia, and 3) preventing hyperglycemia-induced BBB disruption. Hence, we suggest that melatonin would be a key in attenuating the pathogenesis of type 3 diabetes.

**Abbreviations**
AD: Alzheimer’s disease; Aβ: Beta amyloid; BBB: Blood brain barrier; CNS: Central nervous system; CSF: Cerebrospinal fluid; GLUT: Glucose transporter; Glut1: Glucose transporter 1; GSK-3: Glycogen synthase kinase; HIF-1α: Hypoxia-inducible factor-1α; IFN-γ: Interferon –gamma; IL-6: interleukin-6; IRS: Insulin receptors; MCI: Mild cognitive impairment; MT1: Melatonin receptor 1; NFT: Intracellular neurofibrillary tangles; PI3K: Phosphoinositol-3-kinase; ROS: Reactive oxygen species; STZ: Streptozotocin; T1DM: Type 1 diabetes; T2DM: Type 2 diabetes; TNF-α: tumor necrosis factor-α; VEGF: Vascular endothelial growth factor
Acknowledgements

This study was supported by the Brain Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning NRF-2016M3C7A1905469 (B.K.) and a grant from 2016R1D1A1B03930394 (J.S.).

Funding

All sources of funding (the Ministry of Science, ICT & Future Planning NRF-2016M3C7A1905469 & - 2016R1D1A1B03930394) for the research declare the support of the funding in collecting references and in writing the manuscript.

Availability of data and materials

Not applicable.

Authors’ contributions

JS contributed to writing the preliminary draft of this manuscript. DJW revised the overall manuscript with a logical argument. BCK revised the manuscript as a whole. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Biomedical Sciences, Center for Creative Biomedical Scientists at Chonnam National University, Gwangju 61469, South Korea.
2Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, School of Clinical Sciences, Faculty of Healthy Sciences, University of Bristol, Whitson street, Bristol BS1 3NY, UK. 3Department of Neurology, Chonnam National University Medical School, Gwangju 61469, South Korea.

Received: 17 January 2017 Accepted: 12 July 2017

Published online: 01 August 2017

References

1. Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741–66.
2. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet. 2011;377(9768):1019–31.
3. Alzheimer’s Association National Plan Milestone W, Fargo KN, Aisen P, Albert M, Au R, Corrada MM, et al. 2014 report on the milestones for the US National Plan to address Alzheimer’s disease. Alzheimers Dement. 2014;10(5 Suppl):S430–52.
4. Gulland A. Number of people with dementia will reach 65.7 million by 2030, says report. BMJ. 2012;344:e3604.
5. Zhang G, Xie Y, Wang W, Feng X, Jia J. Clinical characterization of an APP mutation (V717I) in five Han Chinese families with early-onset Alzheimer’s disease. J Neurol Sci. 2016;369:1–5.
6. Cuccaro ML, Carney RM, Zhang Y, Bohm C, Kunkle BW, Vardarajan BN, et al. SORL1 rs1699102 polymorphism modulates age-related cognitive decline and gray matter volume reduction in non-demented individuals. Eur J Neurol. 2016; doi:10.1111/ejn.13182.
7. Na HK, Kang DR, Kim S, Seo SW, Heo KM, Noh Y, et al. Malignant progression in panela-dominant atrophy subtype of Alzheimer’s disease occurs independent of onset age. Neurobiol Aging. 2016;47:149–56.
8. Dominguez LJ, Barbagallo M. Dietary approaches and supplements in the prevention of cognitive decline and Alzheimer’s disease. Curr Pharm Des. 2016;22(6):688–700.
9. Ashe KH, Zahr KS. Probing the biology of Alzheimer’s disease in mice. Neuron. 2010;66(5):631–43.
10. de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimers Dis. 2005;7(1):45–61.
11. Craft S. Alzheimer disease: insulin resistance and AD-extending the translational path. Nat Rev Neurol. 2012;8(7):360–2.
12. Biesels GJ, Staekenborg S, Brunner E, Bayne C, Scheltens P. Role of diabetes in dementia: a systematic review. Lancet Neurol. 2006;5(1):164–74.
13. Lin B, Hasegawa Y, Kobuchi N, Cao C, Kim-Mitsuyama S. High-Fat-Diet Intake Enhances Cerebral Amyloid Angiopathy and Cognitive Impairment in a Mouse Model of Alzheimer’s Disease, Independently of Metabolic Disorders. J Am Heart Assoc. 2016;5(6):e003154. doi:10.1161/JAHA.115.003154.
14. Weihrich KM, Sherry DM. Role of melatonin and its receptors in the diabetic retina. Int Rev Cell Mol Biol. 2013;300:211–42.
15. Chen CY, Logan RW, Ma T, Lewis DA, Tseng GC, Sibille E, et al. Effects of aging on circadian patterns of gene expression in the human prefrontal cortex. Proc Natl Acad Sci U S A. 2016;113(12):2061–11.
16. Manchester LC, Coto-Montes A, Boga JA, Andersen LP, Zhou Z, Galano A, et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res. 2015;59(4):403–19.
17. Moretti R, Zanin A, Pansiot J, Spin D, Manganozzi L, Kratzer L, et al. Melatonin reduces excitotoxic blood-brain barrier breakdown in neonatal rats. Neuroscience. 2015;311:382–97.
18. Hardeled R, Cardinali DP, Brown GW, Pandi-Perumal SR. Melatonin and brain inflammation. Prog Neurobiol. 2015;127:128–46–63.
19. Pistacchi M, Gioulis M, Contin F, Sanson F, Marsala S. Sleep disturbance and cognitive disorder: epidemiological analysis in a cohort of 263 patients. Neurosci Lett. 2014;535(1):195–62.
20. Cipriani G, Lucetti C, Danti S, Nut S. Sleep disturbances and dementia. Psychogeriatrics. 2015;15(1):65–74.
21. Song Q, Feng G, Huang Z, Chen X, Chen Z, Ping Y. Aberrant axonal Arborization of PDH neurons induced by Abeta42-mediated JNK activation underlies sleep disturbance in an Alzheimer’s model. Mol Neurobiol. 2016; doi:10.1007/s12035-016-0165-2.
22. Ooms S, Ju YE. Treatment of sleep disorders in dementia. Curr Treat Options Neurol. 2016;18(9):40.
23. Zhang W, Chen XY, Su SW, Jia QZ, Ding T, Zhu ZN, et al. Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials. Neurol Sci. 2016;37(1):57–65.
36. Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res. 2005;38(1):145–52.
37. Zhou JN, Liu RY, Kamphorst W, Hoffman MA, Swaab DF. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res. 2003;35(2):125–30.
38. Rudnitskaya EA, Muraleva NA, Makimova KY, Kiselya E, Kolosova NG, Stefanova NA. Melatonin attenuates memory impairment, amyloid-beta accumulation, and neurodegeneration in a rat model of sporadic Alzheimer's disease. J Alzheimers Dis. 2015;47(1):103–16.
39. Ali T, Kim MO. Melatonin ameliorates amyloid beta-induced memory deficits, tau hyperphosphorylation and neurodegeneration via PI3/Akt/GSK3beta pathway in the mouse hippocampus. J Pineal Res. 2015;59(1):47–59.
40. Stefanova NA, Makimova KY, Kiselya E, Rudnitskaya EA, Muraleva NA, Kolosova NG. Melatonin attenuates impairments of structural hippocampal plasticity in OXYS rats during active progression of Alzheimer's disease-like pathology. J Pineal Res. 2015;59(2):163–77.
41. Alluri H, Wilson RL, Anasooya Shaji C, Wiggins-Dohlvik K, Patel S, Liu Y, et al. Melatonin preserves blood-brain barrier integrity and permeability via matrix metalloproteinase-9 inhibition. PLoS One. 2016;11(5):e0154427.
42. Peschke E, Frese T, Chankeiwitze E, Peschke D, Press U, Schneyer U, et al. Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J Pineal Res. 2006;40(2):135–43.
43. Contreras-Alcantara S, Baba K, Tosini G. Removal of melatonin receptor type 1 induces insulin resistance in the mouse. Obesity (Silver Spring). 2010;18(9):1861–3.
44. Rubio-Sastre P, Schnee F, Gomez-Abellan P, Madrid JA, Garasult M. Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. Sleep. 2014;37(10):1715–9.
45. Kendall DM, Bergenstal RM. Comprehensive management of patients with type 2 diabetes: establishing priorities of care. Am J Manag Care. 2001;7(10 Suppl):S327–43–quiz 544–8.
46. Blaker E. Sleep and society: an epidemiological perspective. Sleep Med. 2009;10(Suppl):S31–45.
47. Banks WA, Owen JB, Erickson MA. Insulin in the brain: there and back again. Mol Neurobiol. 2012;46(1):4–27.
48. Bixler E. Sleep and society: an epidemiological perspective. Sleep Med. 2009;10(11):4453–7.
49. Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A. 2009;106(1):4453–7.
50. Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res. 2005;38(1):145–52.
51. Holscher C. Diabetes as a risk factor for Alzheimer's disease: insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease—is this type 3 diabetes? J Alzheimers Dis. 2005;7(1):63–80.
52. Harvankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature. 1978;272(5656):827–9.
53. Bou-Hallouf S, Zicky Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab. 2009;296(4):E581–91.
54. Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y, et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem. 2003;278(46):45937–45.
55. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer’s disease: implications for treatment. CNS Drugs. 2003;17(1):27–45.
56. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer’s disease. Curr Alzheimer Res. 2012;9(3):135–66.
57. de la Monte SM, Derda Z, Wands JR. Alcohol, insulin resistance and the liver-brain axis. J Gastroenterol Hepatol. 2011;27(Suppl 2):33–41.
58. de la Monte SM. Brain insulin resistance and Alzheimer’s disease-like pathology. J Alzheimers Dis. 2013;36(1):339–49.
59. de la Monte SM, Derda Z, Wands JR. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2011;68(1):51–7.
60. Talbot K, Wang HY, Kazi H, Han LV, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316–31.
61. de la Monte SM, Longato L, Tong M, Wands JR. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs. 2009;10(10):1049–60.
62. Nelson TJ, Sun MK, Hongpaishan J, Alkon DL. Insulin, PKC signaling pathways and synaptic remodeling during memory storage and neuronal repair. Eur J Pharmacol. 2008;585(1):76–87.
63. Steen E, Teny BM, Rivera EI, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—is this type 3 diabetes? J Alzheimers Dis. 2005;7(1):63–80.
64. Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y, et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem. 2003;278(46):45937–45.
65. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer’s disease: implications for treatment. CNS Drugs. 2003;17(1):27–45.
66. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer’s disease. Curr Alzheimer Res. 2012;9(3):135–66.
67. de la Monte SM, Derda Z, Wands JR. Alcohol, insulin resistance and the liver-brain axis. J Gastroenterol Hepatol. 2011;27(Suppl 2):33–41.
68. de la Monte SM. Brain insulin resistance and Alzheimer’s disease-like pathology. J Alzheimers Dis. 2013;36(1):339–49.
69. de la Monte SM, Longato L, Tong M, Wands JR. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs. 2009;10(10):1049–60.
70. Nelson TJ, Sun MK, Hongpaishan J, Alkon DL. Insulin, PKC signaling pathways and synaptic remodeling during memory storage and neuronal repair. Eur J Pharmacol. 2008;585(1):76–87.
133. Zhu LQ, Wang SH, Ling ZQ, Wang DL, Wang JZ. Effect of inhibiting melatonin biosynthesis on spatial memory retention and tau phosphorylation in rat. J Pineal Res. 2004;37(2):71–7.
134. Pullenio P, Mannic T, Sage D, Giovannini L, Salmon P, Lennelli S, et al. Autonomous and self-sustained circadian oscillators displayed in human islet cells. Diabetologia. 2013;56(3):497–507.
135. Shi SQ, Ansari TS, McGuinness OP, Wasserman DH, Johnson CH. Circadian disruption leads to increased resistance and obesity. Curr Biol. 2013;23(5):372–81.
136. Fonken NL, RJ. The effects of light at night on circadian clocks and metabolism. Endocr Rev. 2013;34(4):648–70.
137. Peschke E, Stumpf I, Bazwinsky J, Litvak L, Dralle H, Muhlbauer E. Melatonin and type 2 diabetes - a possible link? J Pineal Res. 2007;42(4):350–8.
138. Salotnik A, Liebmann PM, Stochsmitzy K, Lercher P, Schauenstein K, Klein W, et al. Decreased melatonin synthesis in patients with coronary artery disease. Eur Heart J. 1999;20(18):1314–7.
139. Staiger H, Machicaco F, Schafer SA, Kirhoffer K, Kantartzis K, Guthoff M, et al. Polymorphisms within the novel type 2 diabetes risk locus MTNR1B determine beta-cell function. PLoS One. 2008;3(12):e3962.
140. Bouatta-Najj N, Bonnefond A, Cavaillant-Proenza C, Spano T, Holmkvist J, Marchand M, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009;41(1):89–94.
141. Lysenko V, Nagorny CL, Erods MR, Wierup N, Jonsson A, Spegel P, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009;41(1):82–8.
142. Andersson EA, Stumpf I, Bazwinsky I, Litvak L, Dralle H, Muhlbauer E. Melatonin and type 2 diabetes. Zebrafish. 2013;10(3):275.
143. Sparso T, Bonnefond A, Cavaillant-Proenza C, Spano T, Holmkvist J, Marchand M, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009;41(1):89–94.
144. FangFang LH, Qin T, Li M, Ma S. Thymol improves high-fat diet-induced cognitive deficits in mice via ameliorating brain insulin resistance and upregulating NRF2/ HO-1 pathway. Metab Brain Dis. 2016; doi:10.1007/s11011-016-9921-z.
145. Kothari V, Luo Y, Tornabene T, O'Neill AM, Greene MW, Thangiah G, et al. Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med. 2005;165(8):863–70.
146. Guo C, Zhang S, Li JY, Ding C, Yang ZH, Chai R, et al. Chronic hyperglycemia mediates the insulin-inhibitory effect of melatonin in pancreatic beta-cells. J Pineal Res. 2008;45(3):318–20.
147. Peschke E, Wolgast S, Bazwinsky J, Poncikie K, Muhlbauer E. Increased melatonin synthesis in pineal glands of rats in streptozocin induced type 1 diabetes. J Pineal Res. 2008;45(4):439–48.
148. Zanetta MM, Seraphim PM, Sumida DH, Cipolla-Neto J, Machado UF. Calorie restriction reduces pinealocyte-induced insulin resistance by improving GLUT4 gene expression and its translocation to the plasma membrane. J Pineal Res. 2003;35(3):141–9.
149. Hardeland R, Cardinall D, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin—a pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 2011;93(3):350–84.
150. O'Neill C, Kiley AP, Coakley MF, Manning S, Long-Smith CM. Insulin and IGFI-1 signalling: longevity, protein homeostasis and Alzheimer's disease. Biochem Soc Trans. 2012;40(4):721–7.
151. Hildreth KL, Van Pelt RE, Schwartz RS, Obesity, insulin resistance, and Alzheimer's disease. Obesity (Silver Spring). 2012;20(8):1549–57.
152. Hardestal R, Cardinall D, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin—a pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 2011;93(3):350–84.
153. Peschke E, Wolgast S, Bazwinsky J, Poncike K, Muhlbauer E. Increased melatonin synthesis in pineal glands of rats in streptozocin induced type 1 diabetes. J Pineal Res. 2008;45(4):439–48.
154. Zezi N, Pachter J, McCullough LD, Wolfson L, Kuchel GA. The blood-brain barrier: geriatric relevance of a critical brain-body interface. J Am Geriatr Soc. 2010;58(9):1749–57.
155. Penidesky V, Ramirez SH, Haorah J, Kannmoge GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmunol Pharmacol. 2006;1(3):223–36.
156. Lovell MA, Markesbery WR. Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci. 2007;28(14):3366–40.
157. Osawa A, Maeshima S, Shimamoto Y, Maeshima E, Sekiguchi E, Kakishita K, et al. Relationship between cognitive function and regional cerebral blood flow in different types of dementia. Disabil Rehabil. 2004;26(12):739–45.
158. Fouilloux C, Contreras F, Laires M, Cano R, Leal E, Arnaiz N, et al. Metabolic and hemodynamic markers of endothelial dysfunction in patients with hypertension and patients with type 2 diabetes during the cold pressor test. Am J Ther. 2018;15(4):389–96.
159. Riva CE, Logean E, Falsini B. Visually evoked hemodynamic response and assessment of neurovascular coupling in the optic nerve and retina. Prog Retin Eye Res. 2005;24(2):183–215.
160. Ohman CL, Kleinschmidt TL, Davidson EP, Coppen LJ, Lund DD, Yorek MA. Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes. Vasc Pharmacol. 2008;48(1):47–53.
161. Ryland CM, Geckle MO. Herb and dietary constituents. J Pineal Res. 2003;35(4):318–27.
162. Stumpf I, Bazwinsky J, Peschke E. Modulation of the cGMP pathway in mediating the insulin-inhibitory effect of melatonin in pancreatic beta-cells. J Pineal Res. 2008;42(4):192–201.
163. Prokopenko I, Langenberg C, Saxena R, Soranho N, Thorolessen G, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2010;42(1):77–81.
164. Bazwinsky-Wutschke I, Biekele E, Muhlbauer E, Peschke E. Influence of melatonin receptor signalling on parameters involved in blood glucose regulation. J Pineal Res. 2014;56(1):82–96.
165. Peschke E, Bahr I, Muhlbauer E. Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. Int J Mol Sci. 2013;14(6):6981–7015.
166. Gottlieb DJ, Punjabi NM, Newman AB, Resnick HE, Redline S, Baldwin CM, et al. Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med. 2005;165(19):2158–63.
167. Yaggi HK, Araujo AB, McKnlay JB. Sleep duration as a risk factor for the development of type 2 diabetes. Diabetes Care. 2006;29(3):657–61.
168. Aguir A, El-Hammadi M, Jimenez-Aranda A, Tassi M, Abdo W, Fernandez-Vazquez G, et al. Melatonin reduces hepatic mitochondrial dysfunction in diabetic obese rats. J Pineal Res. 2015;59(1):70–9.
169. Cano Barquilla P, Pagnano ES, Jimenez-Ortega V, Fernandez-Mateos P, Esquifino AI, Cardinall D. Melatonin normalizes clinical and biochemical parameters of mild inflammation in diet-induced metabolic syndrome in rats. J Pineal Res. 2014;57(3):290–9.
170. Piccinni CT, Migliarini B, Olivotto L, Simonelli MP, Goriini E, Carnavelo O. Melatonin and peripheral circulations: insights on appetite and metabolism in Dario Renzo. Zebrafish. 2013;10(3):275–82.
180. Jumnongprakhon P, Govitrapong P, Tocharus C, Tocharus J. Inhibitory effect of melatonin on cerebral endothelial cells dysfunction induced by methamphetamine via NADPH oxidase-2. Brain Res. 1650;2016:84–92.

181. Song J, Kang SM, Lee WT, Park KA, Lee KM, Lee JH. The beneficial effect of melatonin in brain endothelial cells against oxygen-glucose deprivation followed by reperfusion-induced injury. Oxidative Med Cell Longev. 2014;2014:639531.

182. Turgut M, Erdogan S, Ergin K, Serter M. Melatonin ameliorates blood-brain barrier permeability, glutathione, and nitric oxide levels in the choroid plexus of the infantile rats with kaolin-induced hydrocephalus. Brain Res. 2007;1175:117–25.

183. Chen TY, Lee MY, Chen HY, Kuo YL, Lin SC, Wu TS, et al. Melatonin attenuates the postischemic increase in blood-brain barrier permeability and decreases hemorrhagic transformation of tissue-plasminogen activator therapy following ischemic stroke in mice. J Pineal Res. 2006;40(3):242–50.

184. Xie M, Hu A, Luo Y, Sun W, Hu X, Tang S. Interleukin-4 and melatonin ameliorate high glucose and interleukin-1beta stimulated inflammatory reaction in human retinal endothelial cells and retinal pigment epithelial cells. Mol Vis. 2014;20:921–8.